Pfizer and BioNTech to supply the European Union with up to 1.8 billion additional doses of COMIRNATY®
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses.
European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
AstraZeneca COVID-19 vaccine Vaxzevria authorised for emergency use in Japan
- Details
- Category: AstraZeneca
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisation of individuals aged 18 years and older, to prevent COVID-19 caused by SARS-CoV-2.
Takeda announces approval of Moderna's COVID-19 vaccine in Japan
- Details
- Category: Takeda
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna's mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan.
Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment
- Details
- Category: Novartis
Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was supplied without profit to malaria-endemic countries around the globe.
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
- Details
- Category: Sanofi
The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who have recovered from COVID-19, in all adult age groups in a Phase 2 study with 722 volunteers. A global pivotal Phase 3 study is expected to start in the coming weeks.
Lilly and MiNA Therapeutics announce saRNA research collaboration
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company (NYSE: LLY) and MiNA Therapeutics Limited, a pioneer in RNA activation therapeutics, announced a global research collaboration to develop novel drug candidates using MiNA's proprietary small activating RNA (saRNA) technology platform.
More Pharma News ...
- Vaccination with Sputnik V launched in India
- Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study
- Novavax Announces positive preclinical data for combination influenza and COVID-19 vaccine candidate
- Pfizer and BioNTech to provide COVID-19 caccine doses for olympic athletes at the 2020 Tokyo Games
- Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
- Moderna announces emergency use listing granted by the World Health Organization for its COVID-19 vaccine
- Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche's Actemra/RoActemra®